Datamonitor's October edition of the CNS Review brings you the latest news, analysis and research in the CNS industry.

It covers all the major current business issues and events, including R&D, licensing deals, alliances and joint ventures, and regulatory decisions.

Scope

• Strategic insight into the future shape of CNS companies and markets

• The most significant CNS industry news compiled into one monthly update

• Expert analysis into the implications of the month's important CNS industry events

• Insight into the future shape of the market for players at all levels

• All the month's CNS stories in headline and summary form

Report Highlights

Out of the dozens of topics covered in this month's review, the most important include:

* Novartis and Orion Pharma filed a New Drug Application with the FDA to market the first triple combination product for the treatment of Parkinson's disease. This new product combines levodopa, carbidopa and entacapone.

* A US court pulled a GlaxoSmithKline television advert for Paxil, after finding that claims that the antidepressant was 'non-habit forming' were false. The district court judge also said that plaintiffs had a 'reasonable likelihood' of winning negligence, fraud and deficit claims against GSK.

Reasons to Purchase

• Not only keeps you updated about industry events - it also gives you opinion and insight

• Draws upon Datamonitor analysts' extensive experience to bring you our perspective on the impact of the latest events

• Provides you with your own news archive to track company and industry progress, giving you an extensive reference to relevant events and issues

R&D UPDATE: ALZHEIMER'S DISEASE

The most significant news in Alzheimer's disease R&D, compiled into one monthly update.

R&D UPDATE: DEPRESSION

The most significant news in depression R&D, compiled into one monthly update.

R&D UPDATE: EPILEPSY

The most significant news in epilepsy R&D, compiled into one monthly update.

R&D UPDATE: MIGRAINE

The most significant news in migraine R&D, compiled into one monthly update.

R&D UPDATE: MULTIPLE SCLEROSIS

The most significant news in multiple sclerosis, compiled into one monthly update including:

R&D UPDATE: OTHER CNS

The most significant news in other CNS, compiled into one monthly update including:

• Lou Gehrig's

• Autism

• Schizophrenia

LATEST COMMENT

Expert analysis of the implications of the month's important industry events

• Forest/Lundbeck: left-handed may not be much better

• GSK: stuck in the middle as regulator fights judge

• GlaxoSmithKline: bipolar filing for Lamictal

• Alzheimer's disease: drug trial comes under fire

FEATURE ANALYSIS

Analyst-written feature articles, featuring the latest insights into the industry

• Pink Viagra: revolutionizing female sexual dysfunction treatment?

• Postnatal depression: industry action long overdue

NEWS HEADLINES - ALZHEIMER'S DISEASE

All the month's Alzheimer's disease news stories in headline and summary form

NEWS HEADLINES - DEPRESSION

All the month's depression news stories in headline and summary form

NEWS HEADLINES - EPILEPSY

All the month's epilepsy news stories in headline and summary form

NEWS HEADLINES - MIGRAINE

All the month's migraine news stories in headline and summary form

NEWS HEADLINES - MULTIPLE SCLEROSIS

All the month's multiple sclerosis news stories in headline and summary form

NEWS HEADLINES - OTHER CNS

All the month's other CNS news stories in headline and summary form

To order - click here!